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Introduction. The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in
myositis, scleroderma, and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial, and
studies are lacking for clarifying the association of anti-Ro52 with interstitial lung disease (ILD) in connective tissue diseases
(CTD). Objectives. To determine if anti-Ro52 antibodies are associated with ILD in CTD other than scleroderma. Methods. Single-
center, retrospective study based on immunoblotting panel analysis and patients clinical records. Results. In our connective tissue
disease cohort, 162 patients had immunoblotting panels with anti-Ro52 reactivity analysis, 41 (25,3%) had inclusion criteria.
Among the 41 selected sera, 85.4% (n = 35) had anti-Ro52 reactivity. The prevalence of ILD in the positive anti-Ro52 antibodies
was 71.4% (n = 25), and 16.7% (n = 1) in the negative anti-Ro52 group (P = 0.018). Overall sensitivity (96.2%), specificity
(83.3%), positive (71.4%) and negative (83.3%) predictive values of anti-Ro52 antibodies to determine ILD in CTD is detailed in
this study. Conclusion. Ro52 autoantibodies are associated with ILD in CTD excluding scleroderma. We suggest that the presence
of anti-Ro52 reactivity in CTD should increase the clinician curiosity for the search of ILD.
1. Introduction
Antibodies to SSA antigen (Ro52/Ro60) were historically
described as a marker for Sjo¨gren syndrome and systemic
lupus erythematosus [1]. However, recent publications [2, 3]
have demonstrated that Ro52 and Ro60 (SSA) antigens
consisted of two diﬀerent proteins representing two distinct
autoantibodies systems and have diﬀerent clinical associa-
tions [4].
The Ro52 gene has been mapped to the end of the short
arm of human chromosome 11 [5], and Ro52 antigen has
recently been identified as a 52 kDa protein, belonging to
the tripartite motif (TRIM) protein family [6]. So, anti-Ro52
antibodies can also be named as anti-TRIM21 antibodies.
The presence of anti-Ro52 antibodies has been reported
in a wide variety of autoimmune diseases, particularly in
myositis, scleroderma, and autoimmune liver diseases [7, 8].
These antibodies have also been associated with nonau-
toimmune diseases such as viral infections and neoplastic
diseases [9]. Despite these associations, the clinical signifi-
cance of anti-Ro52/TRIM21 antibodies remains controver-
sial [10, 11].
As previously reported [7, 12], anti-Ro52 is the most
common autoantibody detected in polymyositis with anti-
synthetase syndrome. Some studies report an association of
anti-Ro52 antibodies with aggressive anti-tRNA synthetases
syndrome [13, 14].
The main clinical reported data associate anti-Ro52
antibodies with interstitial lung disease (ILD) [7]. The reason
why anti-Ro2 antibodies cause ILD is not established. It has
been described that Ro52 targets many transcription factors
to disregulate proinflammatory cytokine production belong-
ing to the IL23-TH17 pathway and links to the development
of tissue-specific inflammation and systemic autoimmunity
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[15]. Some authors find an association between the presence
of anti-Ro52 antibodies and pulmonary infections. This
association may be related to the gene location of Ro52
antigen on human chromosome 11. Also, the chromosome
11 (p15.5 segment) may harbor genes involved in the
development and progression of lung cancer, and the Ro52
is a candidate tumor suppressor because of its function as a
transcriptional regulator [15].
The paucity of information regarding our ability to
predict pulmonary involvement in patients with connective
tissue disease has led to the development of this study.
2. Objective
Our objective is to determine if anti-Ro52 antibodies are
associated with interstitial lung disease (ILD) in connective
tissue diseases (excluding scleroderma).
3. Methods
3.1. Studied Population. Single center, retrospective study
based on immunoblotting panels (EUROLINE) analysis and
patients clinical records. All patients who had been screened
for anti-Ro52 reactivity and were listed in the database of the
immunology laboratory of our University Hospital in Porto
between 1 January 2010 and 1 June 2011 were investigated.
Autoimmune disease (AD) was defined when a patient
displayed one of these: myositis with or without antisyn-
thetase antibodies, systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), Sjo¨gren syndrome (SS), and
mixed connective tissue disease (CTD). All in accordance
with the international criteria for classification [16, 17].
Undiﬀerentiated connective tissue disease (UCTD) was
defined as an autoimmune disorder in which signs and
symptoms are widely variable and evocative for connectivitis
but not suﬃciently evolved to fulfil any of the accepted clas-
sification criteria for the defined connective tissue diseases.
Paraneoplastic syndrome was defined when a patient had
a connective tissue manifestation of an established primary
neoplasm.
3.2. Exclusion Criteria. Patients without connective tissue
disease (CTD) diagnosis criteria as defined above, whose
clinical records were insuﬃcient, and patients without a
pulmonary computed tomography (CT) scan were excluded.
Patients with systemic sclerosis (SSc) and autoimmune
hepatitis were excluded. Concerning SSc, this study is under
development by the same authors.
3.3. Definitions. ILD was defined as alveolitis (ground glass
changes) and/or fibrosis, determined by radiologist inter-
pretation of high-resolution CT scan (HRCT). Whenever
possible, these alterations were supported by nonspecific
inflammatory changes (lymphocyte predominance) in bron-
choalveolar lavage (BAL) results.
3.4. Data Analysis. Data were registered in Excel, and SPSS
software was used for statistical analysis.
For proportion analysis, chi-square or Fisher tests were
used. A significance (P) < 0,05 was defined.
Complementary information in data analysis is men-
tioned along the text and tables.
4. Results
Of 162 immunoblotting panels analyzed for anti-Ro52
reactivity, 41 (25.3%) had inclusion criteria: 78% (n = 32)
were women and 22% (n = 9) were men, mean (SD) age
50.5 (15.4) years.
We had to exclude 121 patients. The reasons were (1)
no clear diagnosis (n = 24) of connective tissue disease
(e.g., isolated Raynaud, arthralgia, dermatologic, and/or
nonspecified pulmonary alterations), (2) inexistence of
pulmonary HRCT scan (n = 53), and (3) patients from other
centers (we had no access to clinical data of these patients)
whose immunoblotting panels were processed in our center
(n = 44).
Among the 41 selected sera, 85.4% (n = 35) were positive
for anti-Ro52 autoantibodies.
The gender distribution and mean age (SD) in the
positive anti-Ro52 group were similar to the initial group
(77.1% women; 50.3 (15) years, resp.).
The prevalence of ILD in the positive anti-Ro52 antibod-
ies was 71.4% (n = 25) and 16.7% (n = 1) in the negative
anti-Ro52 group (P = 0.018).
Most patients had no respiratory symptoms described.
Only the patients with antisynthetase syndrome (n = 5) had
clear respiratory symptoms described and underwent BAL.
Overall sensitivity (96.2%), specificity (83.3%), and
positive (71.4%) and negative (83.3%) predictive values
of anti-Ro52 antibodies for determining ILD in CTD are
detailed in Table 1.
The distribution of positive anti-Ro52 antibodies
through CTD is shown in Table 2. No significant diﬀerences
between CTD were found (P = 0.668).
The distribution of ILD through CTD is detailed in
Table 3. No significant diﬀerences between CTD were found
(P = 0.996).
In absolute numbers, the majority of reported cases were
associated with polymyositis/dermatomyositis (PM/DM),
systemic lupus erythematosus (SLE), and mixed CTD. These
diseases are analyzed separately below.
Concerning the 17 PM/DM cases, 76.5% (n = 13) had
anti-Ro52 reactivity, and 64.7% (n = 11) had ILD. Of
the 11 patients with ILD, 10 (90.0%) were anti-Ro52
reactive. No significant diﬀerences between groups were
found (P = 0.09). In the 11 patient with ILD group, 5
(45.5%) had antisynthetase syndrome with anti-Jo1 positive
autoantibody. All patients with anti-Jo1 antibodies (n = 5)
were also anti-Ro52 positive. No significant diﬀerences
between anti-Ro52 positive and negative groups were found
(P = 0.208).
Analyzing the 9 SLE cases, 77.8% (n = 7) were anti-
Ro52 positive, and 69.7% (n = 6) had ILD. All patients with
ILD were anti-Ro52 positive (100%; n = 6). No significant
diﬀerences between anti-Ro52 positive and negative groups
were found (P = 0.083).
ISRN Rheumatology 3
Table 1: Sensitivity (Ss), specificity (Sp), positive (PPV), and negative (NPV) predictive values of anti-Ro52 reactivity in determining
pulmonary involvement in connective tissue diseases.
ILD PARo52A
(CI 95%)
Ss, % Sp, % PPV, % NPV, %
n = 26 n = 35 96.2 (89–100) 83.3 (53–100) 71.4 (56–86) 83.3 (53–100)
ILD, interstitial lung disease; PARo52A, positive anti-Ro52 antibodies.
Table 2: Distribution of anti-Ro52 antibodies through connective tissue diseases.
PM/DM n (%) SLE n (%) Sjo¨gren n (%) Mixed CTD n (%) U CTD n (%) P Neo n (%) P
PARo52A 13 (76.5) 7 (77.8) 2 (100) 8 (100) 3 (100) 2 (100) 0.668∗
PARo52A, positive anti-Ro52 antibodies; PM/DM, polymyositis dermatomyositis; SLE, systemic lupus erythematosus; CTD, connective tissue diseases; U,
undiﬀerentiated; P Neo, paraneoplastic.
∗Fischer test.
Table 3: Distribution of interstitial lung disease (ILD) through connective tissue diseases (CTD).
PM/DM n (%) SLE n (%) Sjo¨gren n (%) Mixed CTD n (%) U CTD n (%) P Neo n (%) P
ILD 11 (64.7) 6 (69.7) 1 (50) 5 (62.5) 2 (66.7) 1 (50) 0.996∗
PM/DM, polymyositis dermatomyositis; SLE, systemic lupus erythematosus; CTD, connective tissue diseases; U, undiﬀerentiated; P Neo, paraneoplastic.
∗Fischer test.
In the 8 mixed CTD group, 100% (n = 8) were anti-Ro52
positive, and 62.5% (n = 5) had ILD. In this particular case,
no statistics were computed because anti-Ro52 is a constant.
5. Discussion
As described in the introduction, anti-Ro52 antibodies have
been detected in various autoimmune diseases and the main
clinical reported data associate anti-Ro52 antibodies with
ILD. On the other hand, some series do not consistently
associate anti-Ro52 antibodies with autoimmune disease and
find these autoantibodies weakly predictive of autoimmunity
[18, 19].
Given the available data, we can describe the clinical
significance of anti-Ro52 antibodies as controversial.
Our study demonstrates that anti-Ro52 antibodies are
significantly associated with ILD in CTD and are very
sensitive for ILD diagnosis. But they have less value for
confirming and excluding ILD. A multicentric retrospective
study [10] involving 155 patients whose sera was reactive to
Ro52, looked at the clinical relevance of anti-Ro52 antibodies
in autoimmune and nonautoimmune diseases. This study
had a high prevalence of autoimmune diseases (73%). The
prevalence of ILD associated with the presence of anti-Ro52
antibodies was 22% (34/155). These data are consistent with
the data presented in our study.
Whether anti-Ro52 antibodies could be a marker for ILD
independent of the presence of CTD is a question we cannot
answer in this small study. Further and larger studies must be
designed to address this issue.
Anti-Ro52 antibodies are present throughout CTD spec-
trum. When we analyze CTD separately, the diﬀerences
between Ro52 positive and negative groups were not signif-
icant, maybe because absolute numbers were low and only
Fischer tests could be used. Despite of these limitations we
found a tendency towards significant diﬀerences in PM/DM
(P = 0.09) and SLE (P = 0.083). Other studies did not find
value for the positive or diﬀerential diagnosis of AD [19].
All patients (n = 5) with anti-tRNA synthetases syndrome
were anti-Ro52 positive. No significant diﬀerences between
groups were found. Once again low absolute numbers
limited the statistical analysis. The presence of anti-Ro52
antibody could be associated with a poor prognosis or may
precede the development of pulmonary infection in anti-
tRNA synthetases syndrome. Close followup of those patients
should be recommended [20].
Further studies should be addressed to clarify if Ro52
is significantly associated with ILD in each CTD separately,
particularly the antisynthetase syndrome.
Our study has several limitations, the most important
concerning the sample size and retrospective analysis. In our
study, few patients had inclusion criteria (n = 41). The
small sample size limits the power of this study. Given the
heterogeneity of the sample, patients were followed by many
practitioners of diﬀerent areas of specialization. In addi-
tion, there was no standardization in follow-up or clinical
registries. Consequently, we could not describe symptoms
adequately nor assess the longer-term risk of developing
ILD in patients with anti-Ro52 antibodies, and prospective
monitoring is required to evaluate this risk. Finally, we had
to exclude many patients (e.g., patients without pulmonary
HRCT scan).
Despite the great limitations, we find some data ad-
dressed in this study an important matter of discussion.
6. Conclusion
Ro52 autoantibodies are associated with ILD in CTD exclud-
ing scleroderma. In this clinical context, these auto antibod-
ies are very sensitive for ILD diagnosis. We suggest that the
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presence of anti-Ro52 reactivity in CTD should increase the
clinician curiosity for the search of ILD.
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